Sublime

Sterile drug manufacturers are often frustrated by the cost, inefficiencies, and inconsistency of results to freeze-dry their products. Sublime's continuous "cryophilization" process provides drug makers with a means to produce freeze-dried products at one fourth (¼) of the capital costs of traditional processing, while increasing process throughput up to ten times (10X). We are in a position to deliver our first commercial continuous cryophilization machine by Q2'22 (15 months) while attaining a gross markup greater than 100%

Main competitors sell batch equipment using 50 year-old technology.
One is developing a continuous process machine using a completely different drying technology.
Our partnership with a Fortune 500 LN2 Provider, will accelerate completion of the product development and commercialization for our launch.
Team up with Fortune 500 partner's sales and marketing effort to reach largest pharmaceutical manufacturers
Direct sales to medium and smaller manufacturers
Events, Demos, and Digital Campaigns internally and with Agency support
Completed and signed a Joint Development Agreement with our Fortune 500 partner.

Joel Lennon- Meyer, President & Co-Founder
In 2020, while searching for possible components for their lyophilization system, Joel discovered a cryogenic spraying system designed to cool certain powder coating processes. The system source was a Fortune 500 company, which coincidentally had also investigated nutraceutical production. In the fall of 2020, the company approached Sublime with an opportunity for a joint development agreement.

Shawn Stimson, Vice President & Co- Founder
In 2016, Shawn called Joel with an idea for a method to produce high quality lyophilized products, without the traditional cost structure. In typical fashion, they quickly teamed up to validate both science, and business model. The idea matured as they continued their consulting careers, and in 2018, the pair felt they had to move forward. They founded Sublime Stericeuticals.